SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

RENOUNCEABLE NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE

- **LODGEMENT OF OFFER INFORMATION STATEMENT AND UPDATE ON USE OF PROCEEDS FROM RIGHTS CUM WARRANTS ISSUE**

Unless otherwise defined or the context otherwise requires, all capitalised terms used herein bear the same meanings as in the Announcements (as defined below) and the Offer Information Statement (as defined below).

1. INTRODUCTION

The Board of Directors (the "**Board**") of Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**", together with its subsidiaries, collectively, the "**Group**") refers to the Company's announcements dated 30 October 2025, 13 February 2026, 22 April 2026, 12 May 2026 and 20 May 2026 (collectively, the "**Announcements**") in relation to, *inter alia*, the renounceable non-underwritten Rights cum Warrants Issue to be undertaken by the Company.

2. LODGEMENT OF OFFER INFORMATION STATEMENT AND UPDATE ON USE OF PROCEEDS FROM RIGHTS CUM WARRANTS ISSUE

The Board wishes to announce that the Offer Information Statement dated 2 June 2026 in relation to the Rights cum Warrants Issue ("**Offer Information Statement**"), together with its accompanying documents, has been lodged with the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"), acting as agent on behalf of the Monetary Authority of Singapore (the "**Authority**"), on 2 June 2026.

Pursuant to the Securities and Futures (Offers of Investments) (Temporary Exemption from Sections 277(1)(c) and 305B(1)(b)) Regulations 2020, physical copies of the Offer Information Statement will not be despatched to Entitled Shareholders and purchasers of the provisional allotment of Rights Shares with Warrants traded on the SGX-ST ("**Purchasers**"). The Offer Information Statement has instead been made available for viewing online in a Portable Document Format (PDF) at, and may be accessed, downloaded and printed from, the following online locations:

(a) the corporate website of the Company at the following URL:

https://www.advancedmedicine.sg/

(b) the SGXNet announcement page of the Company at the following URL:

https://www.sgx.com/securities/company-announcements?value=SINGAPORE%20INSTITUTE%20OF%20ADVANCED%20MEDICINE%20HOLDINGS%20LTD.&type=company

The Board wishes to highlight that the intended use of proceeds has been revised from that stated in paragraph A (1) (vi) of the Announcement dated 22 April 2026, as disclosed in the Offer Information Statement. For ease of reference, the revised intended use of proceeds disclosed in paragraph 3 of Part 4: Key Information of Disclosure section of the Offer Information Statement is set out in Column (1) below and that disclosed in the Announcement dated 22 April 2026 is set out in Column (2) below:

Proposed use of Net Proceeds	**After Revision**		**Before Revision**	
	(1) **Offer Information Statement Approximate Allocation of Net Proceeds**		**(2)** **Announcement dated 22 April 2026 Approximate Allocation of Net Proceeds**	
	S$	**%**	**S$**	**%**
General working capital	9,440,534	63.19	10,640,534	71.22
Repayment of loan from a Shareholder	1,200,000	8.03	-	-
System maintenance and software upgrades	3,800,000	25.43	3,800,000	25.43
System revamp and CAPEX	500,000	3.35	500,000	3.35
Total	**14,940,534**	**100.00**	**14,940,534**	**100.00**

Please refer to paragraph 3 of Part 4: Key Information of Disclosure Requirements Under the Sixteenth Schedule of the Securities and Futures (Offers of Investments) (Securities and Securities-Based Derivatives Contracts) Regulations 2018 section of the Offer Information Statement for further details.

Rationale for the change of intended use of proceeds:

Due to the longer than expected time to complete the Rights Cum Warrants Issue, the Company obtained an interest-bearing loan of S$1,200,000 from a shareholder to fund its working capital requirements ("**Loan**"), on condition that the Net Proceeds will be utilised towards repayment of the loan. Hence, the intended use of proceeds will have to be changed accordingly. For the avoidance of doubt, the total interest arising from the Loan is less than S$100,000.

3. DESPATCH AND/OR DISSEMINATION OF OIS NOTIFICATION LETTER AND ITS ACCOMPANYING DOCUMENTS

Physical copies of a notification letter containing, *inter alia*, instructions on how to access, download and print the electronic version of the Offer Information Statement ("**OIS Notification Letter**"), together with the Provisional Allotment Letter ("**PAL**") for the Rights Shares with Warrants and/or the application and acceptance form for the Rights Shares with Warrants and Excess Rights Shares with Warrants ("**ARS**" or "**ARE**") (as the case may be), will be despatched to Entitled Shareholders on or around 4 June 2026.

Entitled Depositors who do not receive the OIS Notification Letter, together with the ARE, may contact The Central Depository (Pte) Limited ("**CDP**") via its hotline at +65 6535 7511 or via email at asksgx@sgx.com, on Mondays to Fridays from 8.30 a.m. to 5.00 p.m., during the period from the date the Rights cum Warrants Issue commences up to 5.30 p.m. on 18 June 2026 (or such other time(s) and/or date(s) as may be announced from time to time by or on behalf of the Company).

Entitled Scripholders who do not receive the OIS Notification Letter, together with the PAL, may obtain a copy from the Share Registrar, Boardroom Corporate & Advisory Services Pte. Ltd., at 1 Harbourfront Avenue, #14-07, Keppel Bay Tower, Singapore 098632, on Mondays to Fridays from 8.30 a.m. to 5.30

p.m., during the period from the date the Rights cum Warrants Issue commences up to 5.30 p.m. on 18 June 2026 (or such other time(s) and/or date(s) as may be announced from time to time by or on behalf of the Company).

Purchasers who do not receive the OIS Notification Letter, together with the ARS, may obtain the same from CDP or the Share Registrar, via the contact details and during the relevant periods set out above.

For practical reasons and in order to avoid any violation of the securities legislation applicable in jurisdictions other than Singapore, the Rights Shares with Warrants will not be offered to, and the Offer Information Statement and its accompanying documents will not be despatched or disseminated to Foreign Shareholders or into any jurisdictions outside Singapore. Foreign Shareholders will not be entitled to participate in the Rights cum Warrants Issue. Accordingly, no provisional allotment of the Rights Shares with Warrants will be made to Foreign Shareholders and no purported acceptance of and application for the Rights Shares with Warrants by any Foreign Shareholder will be valid.

4. ACCEPTANCES OF PROVISIONAL ALLOTMENTS OF RIGHTS SHARES WITH WARRANTS AND (IF APPLICABLE) APPLICATION FOR EXCESS RIGHTS SHARES WITH WARRANTS

Acceptances of the provisional allotments of Rights Shares with Warrants and (if applicable) applications for Excess Rights Shares with Warrants may be made by Entitled Shareholders:

(a) in the case of Entitled Depositors, by way of the ARS or the ARE through CDP; and/or by way of an Electronic Application through an ATM of the Participating Bank or an accepted electronic Service; or

(b) in the case of Entitled Scripholders, by way of the PAL through the Share Registrar.

For SRS Investors and investors who hold Shares through finance companies and/or Depository Agents, acceptances of the provisional allotments of Rights Shares with Warrants and (if applicable) applications for Excess Rights Shares with Warrants must be done through their respective SRS Approved Banks with whom they hold their SRS accounts, and their respective finance companies and/or Depository Agents, as the case may be. Such investors are advised to provide their respective finance companies, Depository Agents and/or relevant banks, as the case may be, with the appropriate instructions early in order for such intermediaries to make the relevant acceptance and (if applicable) applications for Excess Rights Shares with Warrants on their behalf by the Closing Date. Any acceptance of the Rights Shares with Warrants and/or (if applicable) applications for Excess Rights Shares with Warrants made directly through CDP, the Share Registrar and/or the Company, as well as Electronic Applications at ATMs of the Participating Bank or through an Accepted Electronic Service, will be rejected.

More information on the procedures for, and terms and conditions applicable to, acceptances, renunciation, splitting and/or sale of the Nil-Paid Rights and for the applications for Excess Rights Shares with Warrants, including the different modes of acceptances or applications and payments are set out in the Offer Information Statement, the ARS, the ARE and the PAL.

5. TRADING PERIOD OF NIL-PAID RIGHTS

The trading period for the Nil-Paid Rights on the SGX-ST will commence from 9.00 a.m. on 4 June 2026 and will end at 5.00 p.m. on 12 June 2026.

Entitled Depositors who sell their Nil-Paid Rights during this period need not forward the ARE to the Purchasers as arrangements will be made by CDP for a separate ARS to be issued to the Purchasers. Purchasers should note that CDP will, for and on behalf of the Company, send the OIS Notification Letter and the ARS, **BY ORDINARY POST AND AT THE PURCHASERS' OWN RISK**, to their respective Singapore addresses as maintained in the records of CDP.

For practical reasons and in order to avoid any violation of the securities legislation applicable in jurisdictions other than Singapore, the Offer Information Statement and its accompanying documents will also not be despatched or disseminated to persons purchasing the Nil-Paid Rights, whose registered addresses with CDP are outside Singapore as at the Record Date ("**Foreign Purchasers**").

Foreign Purchasers who wish to accept the Nil-Paid Rights credited by CDP to their Securities Accounts should make the necessary arrangements with their respective Depository Agents or stockbrokers in Singapore. The Company further reserves the right to reject any acceptances of the Rights Shares with Warrants and/or application for Excess Rights Shares with Warrants where it believes, or has reason to believe, that such acceptance and/or application may violate the applicable legislation of any jurisdiction. The Company assumes no responsibility in the event there is a violation by any person of such legislation.

6. INDICATIVE TIMETABLE OF KEY EVENTS

An indicative timetable for the Rights cum Warrants Issue is set out below (all references are to Singapore dates and times) and is subject to change. Please note that the indicative timetable below is provided on the basis that the Rights Shares with Warrants will be listed and quoted on the Catalist. For the events listed which are described as "expected", please refer to future announcement(s) by the Company and/or the SGX-ST for the exact dates of these events.

Last day Shares trade cum-rights	:	26 May 2026
Shares trade ex-rights	:	28 May 2026 from 9.00 a.m.
Record Date	:	29 May 2026 at 5.00 p.m.
Date of lodgement of the Offer Information Statement with the SGX-ST, acting as agent on behalf of the Authority	:	2 June 2026
Despatch of OIS Notification Letter (together with the PAL, ARE or ARS, as the case may be) to Entitled Shareholders with instructions on how they can access the electronic version of the Offer Information Statement	:	4 June 2026
Commencement of trading of Nil-Paid Rights	:	4 June 2026 from 9.00 a.m.
Commencement of application for Rights Shares with Warrants	:	4 June 2026
Last date and time for splitting and trading of Nil-Paid Rights	:	12 June 2026 at 5.00 p.m.
Last date and time for acceptance of and payment for Rights Shares with Warrants and Excess Applications (including by renouncees) (1)	:	18 June 2026 at 5.30 p.m. (or 9.30 p.m. for Electronic Applications through ATMs of the Participating Bank)
Expected date for issuance of Rights Shares	:	25 June 2026
Expected date for issuance of Warrants	:	25 June 2026
Expected date for crediting of Rights Shares with Warrants	:	26 June 2026
Expected date for refund of unsuccessful or invalid applications (if made through CDP)	:	26 June 2026
Expected date and time for the listing and commencement of trading of Rights Shares on the SGX-ST	:	26 June 2026 at 9.00 a.m.
Expected date and time for the listing and commencement of trading of Warrants on the SGX-ST (subject to there being an adequate spread of holdings of the Warrants to provide an orderly market in the trading of the Warrants)	:	29 June 2026 at 9.00 a.m.

Note:

(1) Investors who hold Shares through finance companies or Depository Agents (including but not limited to SRS Investors), where applicable, will receive notification letter(s) from their respective SRS Operators with whom they hold their SRS Accounts, finance companies and/or Depository Agents (as the case may be), and should refer to such notification letter(s) for details of the last date and time to submit applications to their respective SRS Approved Banks with whom they hold their SRS Accounts, finance companies and/or Depository Agents (as the case may be). Any acceptance of the Rights Shares with Warrants and (if applicable) Excess Applications made or purported to be made by these investors directly through CDP, the Share Registrar, the Company and/or by way of Electronic Application at any ATM of the Participating Bank or Accepted Electronic Service will be rejected. SRS Investors and investors who hold Shares through a finance company and/or Depository Agent should see the section entitled "Important Notice to SRS Investors and Investors who hold Shares through a Finance Company and/or Depository Agent" of the Offer Information Statement.

Pursuant to Rule 820(1) of the Catalist Rules, the Rights cum Warrants Issue cannot be withdrawn after the Shares have commenced ex-rights trading. Based on the above timetable, the Shares have commenced ex-rights trading on 28 May 2026 from 9.00 a.m.

The above timetable is indicative only and is subject to change. As at the Latest Practicable Date, the Company does not expect the above timetable to be modified. However, the Company may, upon consultation with its advisers, and with the approval of the SGX-ST, the Sponsor and/or CDP, modify the above timetable subject to any limitations under any applicable laws, rules or regulations. In such an event, the Company will publicly announce any modification to the above timetable through an SGXNET announcement to be posted on the SGX-ST's website at https://www.sgx.com.

Please note that if there is an insufficient spread of holdings for the Warrants to provide for an orderly market in the trading of the Warrants, the Warrants may not be listed and will be issued in registered form by way of Warrant Certificates and the Company will release further announcement(s) at the relevant time. In which case, the above indicative timetable may be amended and the Company will release further announcement(s) as may be appropriate. Where necessary, the Deed Poll may be amended without the consent of holders of the Warrants to address such scenario.

7. GENERAL

This announcement is qualified in its entirety by, and should be read in conjunction with, the full text of the Offer Information Statement lodged with the SGX-ST acting as agent on behalf of the Authority.

The Company will make further announcements in relation to the Rights cum Warrants Issue, as and when required.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
2 June 2026

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.